Home  |  Contact

Cellosaurus HCT 116 (CVCL_0291)

[Text version]

Cell line name HCT 116
Synonyms HCT-116; HCT.116; HCT_116; HCT116; CoCL2
Accession CVCL_0291
Resource Identification Initiative To cite this cell line use: HCT 116 (RRID:CVCL_0291)
Comments Part of: AstraZeneca Colorectal cell line (AZCL) panel.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 3.
Part of: FGFR genetic alteration cell panel (ATCC TCP-1034).
Part of: JFCR39 cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI RAS program mutant KRAS cell line panel.
Part of: NCI-60 cancer cell line panel.
Doubling time: 17.1 hours (PubMed=22628656); 22 hours (PubMed=23546019); 36 hours (PubMed=25984343); 18.14 +- 0.051 hours (PubMed=32927768); 17.4 hours (NCI-DTP); ~25-48 hours (DSMZ); ~21 hours (PBCF).
Microsatellite instability: Instable (MSI-high) (PubMed=9000147; PubMed=10674020; PubMed=23671654; PubMed=24042735; PubMed=25926053; PubMed=28683746; PubMed=31068700; Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep phosphoproteome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative phosphoproteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: HLA class I peptidome analysis by proteomics.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: miRNA expression profiling.
Omics: N-glycan profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: HCT-166; In BTO BTO:0004743, now obsoleted.
Misspelling: HTC 116; Occasionally.
Misspelling: HTC-116; Occasionally.
Misspelling: Htc-116; Occasionally.
Misspelling: HTC116; Occasionally.
Misspelling: HTC1116; Occasionally.
Derived from sampling site: Colon.
Sequence variations Homozygous for ACVR2A p.Lys437Argfs*5 (c.1310delA) (dbSNP=rs764719749) (PubMed=12615714; CCLE; Cosmic-CLP).
Heterozygous for BRCA2 p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA) (ClinVar=VCV000267050) (PubMed=17088437; CCLE; Cosmic-CLP).
Heterozygous for CDKN2A p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs) (PubMed=17088437; CCLE).
Heterozygous for CDKN2A p.Asp74fs*21 (c.220delG) (PubMed=17088437).
Heterozygous for CDKN2A p.Glu33Argfs*20 (c.97delG) (CCLE).
Heterozygous for CTNNB1 p.Ser45del (c.133_135delTCT) (ClinVar=VCV000017576) (PubMed=9294210; PubMed=24755471; ATCC; CCLE; Cosmic-CLP).
Heterozygous for EP300 p.Met1470Cysfs*22 (c.4408delA) (CCLE; Cosmic-CLP).
Heterozygous for EP300 p.Asn1700Thrfs*9 (c.5099delA) (PubMed=10700188; CCLE; Cosmic-CLP).
Heterozygous for KRAS p.Gly13Asp (c.38G>A) (ClinVar=VCV000012580) (PubMed=12068308; PubMed=17088437; PubMed=20570890; PubMed=24755471; PubMed=28683746; CCLE; Cosmic-CLP).
Heterozygous for PIK3CA p.His1047Arg (c.3140A>G) (ClinVar=VCV000013652) (PubMed=17088437; PubMed=20570890; PubMed=24755471; PubMed=28683746; CCLE; Cosmic-CLP).
Homozygous for TGFBR2 p.Lys128Serfs*35 (c.383delA) (ClinVar=VCV000477546) (PubMed=12615714).
Mutation; TP53; none detected (PubMed=9715273; PubMed=15900046; PubMed=16418264).
HLA typing Source: PubMed=15748285
Class I
Class II

Source: PubMed=25960936
Class I
Class II

Source: PubMed=9178645
Class I
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0.08
East Asian, North1.16
East Asian, South0
South Asian0.97
European, North64.85
European, South32.93
Disease Colon carcinoma (NCIt: C4910)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_JY79 (AT506.C2)CVCL_2299 (ATRFLOX)CVCL_KS06 (CellSensor HRE-bla HCT-116)
CVCL_KS04 (CellSensor LEF/TCF-bla HCT-116)CVCL_KS14 (CellSensor Myc-bla HCT-116)CVCL_KS15 (CellSensor p53RE-bla HCT-116)
CVCL_1Q94 (H414)CVCL_LD40 (HCT 116 ABL1 (T315I/+))CVCL_HG03 (HCT 116 ADAM17)
CVCL_HD66 (HCT 116 AKT1(-/-))CVCL_HD67 (HCT 116 AKT2(-/-))CVCL_LD41 (HCT 116 ALK (F1174L/+))
CVCL_HD68 (HCT 116 APOC1(-/-))CVCL_HG04 (HCT 116 AXL KO Tet-inducible)CVCL_HD69 (HCT 116 BAX(-/-))
CVCL_HD70 (HCT 116 BBC3(-/-))CVCL_HD71 (HCT 116 BLM(-/-))CVCL_LD61 (HCT 116 BRAF (V600A/+))
CVCL_LD62 (HCT 116 BRAF (V600E/+))CVCL_LD63 (HCT 116 BRAF (V600G/+))CVCL_LD64 (HCT 116 BRAF (V600K/+))
CVCL_LD65 (HCT 116 BRAF (V600M/+))CVCL_LD66 (HCT 116 BRAF (V600R/+))CVCL_AS10 (HCT 116 BRCA2(-/-) clone 42)
CVCL_VP26 (HCT 116 BRCA2(-/-) clone 46)CVCL_LD87 (HCT 116 CDK2 (D145N/+))CVCL_HD72 (HCT 116 CDK2(-/-))
CVCL_HD73 (HCT 116 CDKN1A(-/-))CVCL_RJ11 (HCT 116 CMV-OsTIR1)CVCL_HD74 (HCT 116 CTNNB1(+/-))
CVCL_HD75 (HCT 116 DIABLO(-/-))CVCL_HD76 (HCT 116 DICER1(-/-))CVCL_HD77 (HCT 116 DNMT3B(-/-))
CVCL_HG26 (HCT 116 EP300 WT)CVCL_HG05 (HCT 116 EphA2 KO Tet-inducible)CVCL_HD78 (HCT 116 FBXW7(-/-))
CVCL_LD88 (HCT 116 FGFR2 (S252W/+/+))CVCL_LD89 (HCT 116 FGFR3 (S249C/+))CVCL_LD90 (HCT 116 FLT3 (D835Y/+))
CVCL_LD91 (HCT 116 GNA11 (Q209L/+))CVCL_LD92 (HCT 116 GNAQ (Q209L/+))CVCL_LD67 (HCT 116 GNAS (R201C/+))
CVCL_LD68 (HCT 116 IDH1 (R132C/+))CVCL_LD69 (HCT 116 IDH1 (R132H/+))CVCL_LD70 (HCT 116 IDH2 (R140Q/+))
CVCL_LD71 (HCT 116 IDH2 (R172K/+))CVCL_LD93 (HCT 116 JAK2 (V617F/+))CVCL_HD79 (HCT 116 KDM5A(+/-))
CVCL_HD80 (HCT 116 KDM5A(-/-))CVCL_LD94 (HCT 116 KIT (D816V/+))CVCL_HD81 (HCT 116 KRAS(+/-))
CVCL_HD82 (HCT 116 LIG4(+/-))CVCL_HD83 (HCT 116 LIG4(-/-))CVCL_LD95 (HCT 116 MAP2K1 (P124L/+))
CVCL_LD96 (HCT 116 MET (Y1253D/+))CVCL_HD84 (HCT 116 MLH1(+/-))CVCL_LD97 (HCT 116 MTOR (S2035I/+))
CVCL_LD98 (HCT 116 NFE2L2 (E79K/+))CVCL_HD85 (HCT 116 NHEJ1(+/-))CVCL_HD86 (HCT 116 NHEJ1(-/-))
CVCL_LD99 (HCT 116 NOTCH1 (L1601P/+))CVCL_UF05 (HCT 116 NUF2mCherry/mCherry)CVCL_LE00 (HCT 116 PDGFRA (D842V/+))
CVCL_HD87 (HCT 116 PDPK1(+/-))CVCL_LD54 (HCT 116 PIK3CA (H1047R/-))CVCL_RQ06 (HCT 116 PIK3CA H1047R KO)
CVCL_HD88 (HCT 116 PPARD(-/-))CVCL_HD89 (HCT 116 PRKDC(+/-))CVCL_HD90 (HCT 116 PRKDC(-/-))
CVCL_HD91 (HCT 116 PTEN(+/-))CVCL_HD92 (HCT 116 PTEN(-/-))CVCL_HD93 (HCT 116 PTTG1(-/-))
CVCL_HD94 (HCT 116 SFN(-/-))CVCL_QZ52 (HCT 116 shPARG)CVCL_HD95 (HCT 116 SMAD4(-/-))
CVCL_RJ69 (HCT 116 TP53 (R248W/+))CVCL_RJ68 (HCT 116 TP53 (R248W/-))CVCL_HD96 (HCT 116 TP53(+/-))
CVCL_HD97 (HCT 116 TP53(-/-))CVCL_HD98 (HCT 116 USP7(+/-))CVCL_HD99 (HCT 116 USP7(-/-))
CVCL_HE00 (HCT 116 XRCC4(-/-))CVCL_HE01 (HCT 116 XRCC6(+/-))CVCL_HG06 (HCT 116-I6)
CVCL_VU38 (HCT 116-Luc2 [ATCC])CVCL_5J19 (HCT 116-luc2 [Caliper])CVCL_4V73 (HCT 116-OX)
CVCL_5I94 (HCT 116-Red-FLuc)CVCL_4V28 (HCT 116R11)CVCL_4V29 (HCT 116R26)
CVCL_J254 (HCT-116 clone#2-Luc)CVCL_V401 (HCT-116-MEK-R)CVCL_WV82 (HCT-116/SN-38)
CVCL_4V05 (HCT-116/VM34)CVCL_N508 (HCT-116/VM46)CVCL_N509 (HCT-116/VP35)
CVCL_UR40 (HCT116 VIM RFP)CVCL_1R00 (HCT116-53BPI(+/-))CVCL_T770 (HCT116-Artemis(+/-))
CVCL_T771 (HCT116-Artemis(-/-))CVCL_XC97 (HCT116-Cas9-565)CVCL_XC98 (HCT116-Cas9-566)
CVCL_XC99 (HCT116-Cas9-567)CVCL_XD00 (HCT116-Cas9-568)CVCL_XD01 (HCT116-Cas9-TSC22KO-569)
CVCL_1R01 (HCT116-DNAPKcs(+/-))CVCL_5I74 (HCT116-Dual)CVCL_XE63 (HCT116-EGFP)
CVCL_RA37 (HCT116-eGFP-Puro)CVCL_RA38 (HCT116-Fluc-Neo/eGFP-Puro)CVCL_RA39 (HCT116-Fluc-Neo/iRFP-Puro)
CVCL_RA40 (HCT116-Fluc-Puro)CVCL_RA41 (HCT116-hNIS-Neo)CVCL_RA42 (HCT116-hNIS-Neo/eGFP-Puro)
CVCL_RA43 (HCT116-hNIS-Neo/Fluc-Puro)CVCL_RA44 (HCT116-hNIS-Neo/iRFP-Puro)CVCL_RA45 (HCT116-iRFP-Puro)
CVCL_1R02 (HCT116-Ku70(+/-))CVCL_1R03 (HCT116-LIG3(+/-))CVCL_1R04 (HCT116-LIG4(+/-))
CVCL_1R05 (HCT116-MDC1(+/-))CVCL_1R06 (HCT116-MDC1(-/-))CVCL_1R07 (HCT116-POLM(+/-))
CVCL_1R08 (HCT116-RAD18(+/-))CVCL_1R09 (HCT116-RAD18(-/-))CVCL_1R10 (HCT116-REV1(+/-))
CVCL_1R11 (HCT116-REV1(-/-))CVCL_1R12 (HCT116-REV3L(+/-))CVCL_Y553 (HCT116-SN50)
CVCL_Y554 (HCT116-SN6)CVCL_T772 (HCT116-XRCC4(+/-))CVCL_T773 (HCT116-XRCC4(-/-))
CVCL_9796 (HKe-3)CVCL_9797 (HKh-2)CVCL_A9P2 (NF-KappaB reporter (Luc)-HCT-116)
CVCL_4627 (OE47)CVCL_4628 (OE50)CVCL_S744 (p53HCT116)
Originate from same individual CVCL_R729 ! HCT 116a
CVCL_R730 ! HCT 116b
Sex of cell Male
Age at sampling 48Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; KCLB; PubMed=11416159; PubMed=19372543; PubMed=25877200; PubMed=25926053

AmelogeninX (CLS; DSMZ; PubMed=11416159; PubMed=19372543; PubMed=25877200; PubMed=25926053)
X,Y (AddexBio; ATCC; CCRID; Cosmic-CLP; ECACC; KCLB)
CSF1PO7,9,10,11 (Cosmic-CLP)
7,10 (AddexBio; ATCC; CCRID; CLS; DSMZ; ECACC; KCLB; PubMed=11416159; PubMed=19372543; PubMed=25877200; PubMed=25926053)
D3S135812,18,19 (CCRID; CLS)
12,19 (PubMed=19372543; PubMed=25877200)
D8S117910,12,14,15 (CLS)
12,14 (CCRID; PubMed=19372543; PubMed=25877200)
D16S53911,12,13 (DSMZ)
11,13 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; PubMed=19372543; PubMed=25877200; PubMed=25926053)
D18S5116,17 (CCRID; CLS; PubMed=19372543)
17 (PubMed=25877200)
Penta D9,13
Penta E12,13,14 (CLS)
13,14 (PubMed=25877200)
TH018 (DSMZ)
8,9 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; KCLB; PubMed=11416159; PubMed=19372543; PubMed=25877200)
8,9,10 (PubMed=25926053)
TPOX8 (DSMZ; ECACC; KCLB; PubMed=19372543; PubMed=25877200; PubMed=25926053)
8,9 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP)
vWA17 (PubMed=11416159; PubMed=19372543)
17,21 (DSMZ)
17,22 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; KCLB; PubMed=25877200; PubMed=25926053)

Run an STR similarity search on this cell line
Web pages https://en.wikipedia.org/wiki/HCT116_cells

Brattain M.G., Fine W.D., Khaled F.M., Thompson J., Brattain D.E.
Heterogeneity of malignant cells from a human colonic carcinoma.
Cancer Res. 41:1751-1756(1981)

PubMed=6437669; DOI=10.1007/BF00048384
Brattain M.G., Levine A.E., Chakrabarty S., Yeoman L.C., Willson J.K.V., Long B.
Heterogeneity of human colon carcinoma.
Cancer Metastasis Rev. 3:177-191(1984)

PubMed=3955419; DOI=10.3109/07357908609039822
Chakrabarty S., Miller C.A. III, Brattain M.G.
Selective modifications of cellular proteins in intratumoral subpopulations of human colonic carcinoma cells.
Cancer Invest. 4:5-14(1986)

Boyd D., Florent G., Kim P., Brattain M.G.
Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.
Cancer Res. 48:3112-3116(1988)

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=7972006; DOI=10.1073/pnas.91.23.11045
Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B., Serrano M., Beach D.H., Harris C.C.
Mutations and altered expression of p16INK4 in human cancer.
Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)

PubMed=7761852; DOI=10.1126/science.7761852
Markowitz S.D., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J.D., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B., Brattain M.G., Willson J.K.V.
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.
Science 268:1336-1338(1995)

Eshleman J.R., Lang E.Z., Bowerfind G.K., Parsons R., Vogelstein B., Willson J.K.V., Veigl M.L., Sedwick W.D., Markowitz S.D.
Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer.
Oncogene 10:33-37(1995)

Cottu P.H., Muzeau F., Estreicher A., Flejou J.-F., Iggo R.D., Thomas G., Hamelin R.
Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines.
Oncogene 13:2727-2730(1996)

Hoang J.-M., Cottu P.H., Thuille B., Salmon R.J., Thomas G., Hamelin R.
BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines.
Cancer Res. 57:300-303(1997)

PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)

PubMed=9178645; DOI=10.1006/cimm.1997.1108
Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.
CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
Cell. Immunol. 177:176-181(1997)

PubMed=9294210; DOI=10.1073/pnas.94.19.10330
Ilyas M., Tomlinson I.P.M., Rowan A., Pignatelli M., Bodmer W.F.
Beta-catenin mutations in cell lines established from human colorectal cancers.
Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997)

Sparks A.B., Morin P.J., Vogelstein B., Kinzler K.W.
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Cancer Res. 58:1130-1134(1998)

PubMed=9715273; DOI=10.1038/sj.onc.1201986
Eshleman J.R., Casey G., Kochera M.E., Sedwick W.D., Swinler S.E., Veigl M.L., Willson J.K.V., Schwartz S., Markowitz S.D.
Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53.
Oncogene 17:719-725(1998)

PubMed=10674020; DOI=10.1016/S0959-8049(99)00206-3
Ku J.-L., Yoon K.-A., Kim D.-Y., Park J.-G.
Mutations in hMSH6 alone are not sufficient to cause the microsatellite instability in colorectal cancer cell lines.
Eur. J. Cancer 35:1724-1729(1999)

PubMed=10612807; DOI=10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P
Ghadimi B.M., Sackett D.L., Difilippantonio M.J., Schrock E., Neumann T., Jauho A., Auer G., Ried T.
Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations.
Genes Chromosomes Cancer 27:183-190(2000)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V., Jeffrey S.S., van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10700188; DOI=10.1038/73536
Gayther S.A., Batley S.J., Linger L., Bannister A.J., Thorpe K., Chin S.-F., Daigo Y., Russell P., Wilson A., Sowter H.M., Delhanty J.D.A., Ponder B.A.J., Kouzarides T., Caldas C.
Mutations truncating the EP300 acetylase in human cancers.
Nat. Genet. 24:300-303(2000)

PubMed=10737795; DOI=10.1073/pnas.97.7.3352
Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J., Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.
APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.
Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000)

PubMed=11226274; DOI=10.1073/pnas.041603298
Abdel-Rahman W.M., Katsura K., Rens W., Gorman P.A., Sheer D., Bicknell D.C., Bodmer W.F., Arends M.J., Wyllie A.H., Edwards P.A.W.
Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement.
Proc. Natl. Acad. Sci. U.S.A. 98:2538-2543(2001)

PubMed=11314036; DOI=10.1038/sj.onc.1204211
Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R., Minna J.D.
Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.
Oncogene 20:1005-1009(2001)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11526487; DOI=10.1038/sj.onc.1204611
Gayet J., Zhou X.-P., Duval A., Rolland S., Hoang J.-M., Cottu P.H., Hamelin R.
Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines.
Oncogene 20:5025-5032(2001)

PubMed=11687795; DOI=10.1038/ng754
Snijders A.M., Nowak N., Segraves R., Blackwood S., Brown N., Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S., Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N., Pinkel D., Albertson D.G.
Assembly of microarrays for genome-wide measurement of DNA copy number.
Nat. Genet. 29:263-264(2001)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=12584437; DOI=10.1159/000068544
Melcher R., Koehler S., Steinlein C., Schmid M., Mueller C.R., Luehrs H., Menzel T., Scheppach W., Moerk H., Scheurlen M., Koehrle J., Al-Taie O.
Spectral karyotype analysis of colon cancer cell lines of the tumor suppressor and mutator pathway.
Cytogenet. Genome Res. 98:22-28(2002)

Hempen P.M., Zhang L., Bansal R.K., Iacobuzio-Donahue C.A., Murphy K.M., Maitra A., Vogelstein B., Whitehead R.H., Markowitz S.D., Willson J.K.V., Yeo C.J., Hruban R.H., Kern S.E.
Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.
Cancer Res. 63:994-999(2003)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11-11(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133
Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=16418264; DOI=10.1073/pnas.0510146103
Liu Y., Bodmer W.F.
Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006)

PubMed=16854228; DOI=10.1186/1476-4598-5-29
Bandres E., Cubedo E., Agirre X., Malumbres R., Zarate R., Ramirez N., Abajo A., Navarro A., Moreno I., Monzo M., Garcia-Foncillas J.
Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.
Mol. Cancer 5:29-29(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17178751; DOI=10.1093/nar/gkl1030
Fiegler H., Geigl J.B., Langer S., Rigler D., Porter K., Unger K., Carter N.P., Speicher M.R.
High resolution array-CGH analysis of single cells.
Nucleic Acids Res. 35:E15-E15(2007)

PubMed=17363507; DOI=10.1158/1535-7163.MCT-06-0555
Wang J., Kuropatwinski K., Hauser J., Rossi M.R., Zhou Y., Conway A., Kan J.L.C., Gibson N.W., Willson J.K.V., Cowell J.K., Brattain M.G.
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
Mol. Cancer Ther. 6:1143-1150(2007)

PubMed=18258742; DOI=10.1073/pnas.0712176105
Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.
Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.
Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008)

PubMed=18340113; DOI=10.4161/cbt.7.6.5838
Gongora C., Candeil L., Vezzio N., Copois V., Denis V., Breil C., Molina F., Fraslon C., Conseiller E., Pau B., Martineau P., Del Rio M.
Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
Cancer Biol. Ther. 7:822-832(2008)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=19927377; DOI=10.1002/gcc.20730
Knutsen T., Padilla-Nash H.M., Wangsa D., Barenboim-Stapleton L., Camps J., McNeil N.E., Difilippantonio M.J., Ried T.
Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.
Genes Chromosomes Cancer 49:204-223(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192
Janakiraman M., Vakiani E., Zeng Z., Pratilas C.A., Taylor B.S., Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C., Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M., Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Cancer Res. 70:5901-5911(2010)

PubMed=20606684; DOI=10.1038/sj.bjc.6605780
Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.
5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.
Br. J. Cancer 103:340-346(2010)

PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=21912889; DOI=10.1007/s10637-011-9744-z
Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A., Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P., Ding A., Baguley B.C.
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.
Invest. New Drugs 30:2035-2045(2012)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23272949; DOI=10.1186/1755-8794-5-66
Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A., Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A., Orphanides G., French T., Wessels L.F.A.
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.
BMC Med. Genomics 5:66-66(2012)

PubMed=23546019; DOI=10.3892/ijo.2013.1868
Petitprez A., Poindessous V., Ouaret D., Regairaz M., Bastian G., Guerin E., Escargueil A.E., Larsen A.K.
Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.
Int. J. Oncol. 42:1644-1653(2013)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L., Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24042735; DOI=10.1038/oncsis.2013.35
Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknaes M., Hektoen M., Lind G.E., Lothe R.A.
Epigenetic and genetic features of 24 colon cancer cell lines.
Oncogenesis 2:E71-E71(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20-20(2013)

PubMed=23631600; DOI=10.1021/pr400260h
Loftus N.J., Lai L., Wilkinson R.W., Odedra R., Wilson I.D., Barnes A.J.
Global metabolite profiling of human colorectal cancer xenografts in mice using HPLC-MS/MS.
J. Proteome Res. 12:2980-2986(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013
Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.
Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.
Cancer Res. 74:3238-3247(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:E954893-E954893(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25576301; DOI=10.1074/mcp.M114.042812
Bassani-Sternberg M., Pletscher-Frankild S., Jensen L.J., Mann M.
Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
Mol. Cell. Proteomics 14:658-673(2015)

PubMed=25841592; DOI=10.1016/j.jprot.2015.03.019
Piersma S.R., Knol J.C., de Reus I., Labots M., Sampadi B.K., Pham T.V., Ishihama Y., Verheul H.M.W., Jimenez C.R.
Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines.
J. Proteomics 127:247-258(2015)

PubMed=25926053; DOI=10.1038/ncomms8002
Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
Nat. Commun. 6:7002-7002(2015)

PubMed=26169745; DOI=10.1186/s12967-015-0576-z
Halama A., Guerrouahen B.S., Pasquier J., Diboun I., Karoly E.D., Suhre K., Rafii A.
Metabolic signatures differentiate ovarian from colon cancer cell lines.
J. Transl. Med. 13:223-223(2015)

PubMed=26719794; DOI=10.1186/s13742-015-0106-1
Teo A.S.M., Verzotto D., Yao F., Nagarajan N., Hillmer A.M.
Single-molecule optical genome mapping of a human HapMap and a colorectal cancer cell line.
GigaScience 4:65.1-65.6(2015)

PubMed=26537799; DOI=10.1074/mcp.M115.051235
Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J., Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E., Tollenaar R.A., Rombouts Y., Wuhrer M.
N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)/villin mRNA expression.
Mol. Cell. Proteomics 15:124-140(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20-20(2016)

PubMed=28179481; DOI=10.1158/1535-7163.MCT-16-0578
Tanaka N., Mashima T., Mizutani A., Sato A., Aoyama A., Gong B., Yoshida H., Muramatsu Y., Nakata K., Matsuura M., Katayama R., Nagayama S., Fujita N., Sugimoto Y., Seimiya H.
APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer.
Mol. Cancer Ther. 16:752-762(2017)

PubMed=28192450; DOI=10.1371/journal.pone.0171435
Fasterius E., Raso C., Kennedy S., Rauch N., Lundin P., Kolch W., Uhlen M., Al-Khalili Szigyarto C.
A novel RNA sequencing data analysis method for cell line authentication.
PLoS ONE 12:E0171435-E0171435(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28601559; DOI=10.1016/j.cels.2017.05.009
Bekker-Jensen D.B., Kelstrup C.D., Batth T.S., Larsen S.C., Haldrup C., Bramsen J.B., Sorensen K.D., Hoyer S., Orntoft T.F., Andersen C.L., Nielsen M.L., Olsen J.V.
An optimized shotgun strategy for the rapid generation of comprehensive human proteomes.
Cell Syst. 4:587-599.e4(2017)

PubMed=28683746; DOI=10.1186/s12943-017-0691-y
Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J., Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E., Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.
Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.
Mol. Cancer 16:116-116(2017)

PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010
Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C., Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M., Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R., Guinney J., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.
Genomic determinants of protein abundance variation in colorectal cancer cells.
Cell Rep. 20:2201-2214(2017)

PubMed=29101300; DOI=10.15252/msb.20177701
Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R., Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S., Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J., Weichert W., Knapp S., Feller S.M., Kuster B.
Pharmacoproteomic characterisation of human colon and rectal cancer.
Mol. Syst. Biol. 13:951-951(2017)

PubMed=29207035; DOI=10.3892/ijo.2017.4206
Olejniczak A., Szarynska M., Kmiec Z.
In vitro characterization of spheres derived from colorectal cancer cell lines.
Int. J. Oncol. 52:599-612(2018)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051
Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.
Differential effector engagement by oncogenic KRAS.
Cell Rep. 22:1889-1902(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=32172478; DOI=10.1007/s12253-020-00805-3
Xu Y.-T., Zhang L., Wang Q.-L., Zheng M.-J.
Comparison of different colorectal cancer with liver metastases models using six colorectal cancer cell lines.
Pathol. Oncol. Res. 26:2177-2183(2020)

PubMed=32927768; DOI=10.3390/cancers12092582
Schulte am Esch J., Windmoller B.A., Hanewinkel J., Storm J., Forster C., Wilkens L., Kruger M., Kaltschmidt B., Kaltschmidt C.
Isolation and characterization of two novel colorectal cancer cell lines, containing a subpopulation with potential stem-like properties: treatment options by MYC/NMYC inhibition.
Cancers (Basel) 12:2582.1-2582.34(2020)

Cell line collections AddexBio; C0009005/41
BCRC; 60349
BCRJ; 0288
CLS; 300195/p19841_HCT116.html
ECACC; 91091005
ICLC; HTL95025
KCB; KCB 200706YJ
KCLB; 10247
NCBI_Iran; C570
RCB; RCB2979
Cell line databases/resources CLDB; cl1574
CLDB; cl1575
CLDB; cl5198
CCRID; 3111C0001CCC000158
CCRID; 3111C0001CCC000331
CCRID; 3131C0001000700099
CCRID; 3142C0001000001727
Cell_Model_Passport; SIDM00783
ColonAtlas; HCT116
Cosmic-CLP; 905936
DepMap; ACH-000971
Lonza; 691
TOKU-E; 1422
Ontologies BTO; BTO:0001109
CLO; CLO_0003665
EFO; EFO_0002824
MCCL; MCC:0000181
MeSH; D045325
Biological sample resources 4DN; 4DNSRMYUIVGD
BioSample; SAMN03470980
BioSample; SAMN03471481
BioSample; SAMN03473487
BioSample; SAMN05292433
BioSample; SAMN10988251
Chemistry resources ChEMBL-Cells; CHEMBL3308372
ChEMBL-Targets; CHEMBL394
GDSC; 905936
PharmacoDB; HCT116_517_2019
Gene expression databases ArrayExpress; E-MEXP-2623
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-5197
GEO; GSM2143
GEO; GSM50188
GEO; GSM50252
GEO; GSM115118
GEO; GSM206501
GEO; GSM274713
GEO; GSM274714
GEO; GSM274726
GEO; GSM481405
GEO; GSM513818
GEO; GSM514292
GEO; GSM580039
GEO; GSM580040
GEO; GSM741266
GEO; GSM743443
GEO; GSM750773
GEO; GSM750793
GEO; GSM784012
GEO; GSM799331
GEO; GSM799394
GEO; GSM827446
GEO; GSM846355
GEO; GSM887062
GEO; GSM888132
GEO; GSM945287
GEO; GSM945304
GEO; GSM1153399
GEO; GSM1178133
GEO; GSM1178134
GEO; GSM1178135
GEO; GSM1181250
GEO; GSM1181367
GEO; GSM1346874
GEO; GSM1374516
GEO; GSM1374517
GEO; GSM1374518
GEO; GSM1404391
GEO; GSM1404392
GEO; GSM1448092
GEO; GSM1669868
GEO; GSM2124655
GEO; GSM2550001
Metabolomic databases MetaboLights; MTBLS227
Other Wikidata; Q28334584
Polymorphism and mutation databases Cosmic; 711257
Cosmic; 720329
Cosmic; 724840
Cosmic; 869794
Cosmic; 870449
Cosmic; 873701
Cosmic; 875296
Cosmic; 875425
Cosmic; 875847
Cosmic; 876644
Cosmic; 876706
Cosmic; 887223
Cosmic; 889535
Cosmic; 897457
Cosmic; 902790
Cosmic; 905936
Cosmic; 913887
Cosmic; 934564
Cosmic; 947355
Cosmic; 948126
Cosmic; 948861
Cosmic; 985996
Cosmic; 995410
Cosmic; 1043815
Cosmic; 1044257
Cosmic; 1045410
Cosmic; 1057752
Cosmic; 1066205
Cosmic; 1067220
Cosmic; 1092600
Cosmic; 1102383
Cosmic; 1122325
Cosmic; 1131683
Cosmic; 1132568
Cosmic; 1132689
Cosmic; 1154644
Cosmic; 1175840
Cosmic; 1176588
Cosmic; 1183769
Cosmic; 1184080
Cosmic; 1184333
Cosmic; 1187306
Cosmic; 1218874
Cosmic; 1223141
Cosmic; 1305353
Cosmic; 1310945
Cosmic; 1332008
Cosmic; 1436021
Cosmic; 1466804
Cosmic; 1466815
Cosmic; 1479594
Cosmic; 1486132
Cosmic; 1519359
Cosmic; 1524003
Cosmic; 1524333
Cosmic; 1552179
Cosmic; 1571772
Cosmic; 1609495
Cosmic; 1672408
Cosmic; 1676727
Cosmic; 1708402
Cosmic; 1805253
Cosmic; 1927246
Cosmic; 1945865
Cosmic; 1995437
Cosmic; 1998442
Cosmic; 2036656
Cosmic; 2046556
Cosmic; 2052593
Cosmic; 2145576
Cosmic; 2301978
Cosmic; 2389569
Cosmic; 2433755
Cosmic; 2464667
Cosmic; 2550353
Cosmic; 2646766
Cosmic; 2651864
Cosmic; 2667881
Cosmic; 2667972
Cosmic; 2668248
Cosmic; 2727479
Cosmic; 2760068
Cosmic; 2787545
Cosmic; 2811054
IARC_TP53; 21064
LiGeA; CCLE_168
Progenetix; CVCL_0291
Proteomic databases PRIDE; PXD000089
PRIDE; PXD000394
PRIDE; PXD001352
PRIDE; PXD001426
PRIDE; PXD001546
PRIDE; PXD001550
PRIDE; PXD002793
PRIDE; PXD004452
PRIDE; PXD005235
PRIDE; PXD005354
PRIDE; PXD005942
Entry history
Entry creation04-Apr-2012
Last entry update12-Jan-2021
Version number37